Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

BACKGROUND: Dasatinib is a small molecule kinase inhibitor that has recently been shown to inhibit Src family kinases (SFK) and also has activity against CaP. Of importance to metastatic CaP, which frequently metastasises to bone, SFK are also vital to the regulation of bone remodelling. We sought t...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Koreckij, T, Nguyen, H, Brown, L G, Yu, E Y, Vessella, R L, Corey, E
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2009
Предметы:
Translational Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720213/
https://ncbi.nlm.nih.gov/pubmed/19603032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605178
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы